Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma

Background/Aim: Gastrointestinal toxicity is common in patients receiving common therapy of ixazomib with lenalidomide and low-dose dexamethasone (IRd) for relapsed/refractory multiple myeloma. Here, we investigated the safety and effectiveness of ixazomib dosing schedules. Patients and Methods: We...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:In Vivo
Glavni autori: OHASHI, YASUKATA, YATABE, MEGUMI, NIIJIMA, DAISUKE, TANI, KENTARO, OGAWA, CHIAKI, YACHI, YUTAKA, KAGOO, TOSHIYA, BOKU, SAIGEN, UENO, HIRONORI, YANO, TAKAHIRO, HIGAI, KOJI, YOKOYAMA, AKIHIRO
Format: Artigo
Jezik:Inglês
Izdano: International Institute of Anticancer Research 2020
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7652488/
https://ncbi.nlm.nih.gov/pubmed/32871820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.12108
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items